NASDAQ : FOLD
Amicus Therapeutics, Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 14.49 USD (At close: Apr 24, 2026) · Market cap 4.55B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 4.55B |
| Enterprise Value | 4.70B |
Dates
| Measure | Value |
|---|
| Earnings Date | May 6, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 314.00M |
| Shares Outstanding | 314.00M |
| Shares Change (YoY) | +1.31% |
| Shares Change (QoQ) | -0.45% |
| Owned by Insiders (%) | 0.82% |
| Owned by Institutions (%) | 104.68% |
| Float | 311.43M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | 39.70 |
| PS Ratio | 7.17 |
| Forward PS | 5.95 |
| PB Ratio | 16.42 |
| P/TBV Ratio | 72.76 |
| P/FCF Ratio | 152.43 |
| P/OCF Ratio | 137.27 |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | 7.41 |
| EV / EBITDA | 112.00 |
| EV / EBIT | 136.23 |
| EV / FCF | 157.42 |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 2.84 |
| Quick Ratio | 1.72 |
| Debt / Equity | 1.61 |
| Debt / EBITDA | 8.73 |
| Debt / FCF | 14.82 |
| Interest Coverage | 0.75 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -11.58% |
| Return on Assets (ROA) | 2.49% |
| Return on Invested Capital (ROIC) | -1,176.15% |
| Return on Capital Employed (ROCE) | 4.84% |
| Weighted Average Cost of Capital (WACC) | -124.95% |
| Revenue Per Employee | $1.24M |
| Profits Per Employee | -$53,053 |
| Employee Count | 511 |
| Asset Turnover | 0.73 |
| Inventory Turnover | 0.42 |
Taxes
| Measure | Value |
|---|
| Income Tax | 27.30M |
| Effective Tax Rate | 14,293.72% |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 0.48 |
| 52-Week Price Change | +104.09% |
| 50-Day Moving Average | 14.40 |
| 200-Day Moving Average | 10.84 |
| Relative Strength Index (RSI) | 72.15 |
| Average Volume (20 Days) | 2,804,313 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 21.92M |
| Short Previous Month | 21.10M |
| Short % of Shares Out | 6.98% |
| Short % of Float | 7.04% |
| Short Ratio (days to cover) | 6.36 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 634.21M |
| Gross Profit | 561.28M |
| Operating Income | 34.49M |
| Pretax Income | 191,000 |
| Net Income | -27.11M |
| EBITDA | 41.95M |
| EBIT | 34.49M |
| Loss Per Share | -$0.09 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 293.54M |
| Total Debt | 442.36M |
| Net Cash | -148.83M |
| Net Cash Per Share | -$0.47 |
| Equity (Book Value) | 274.24M |
| Book Value Per Share | 0.88 |
| Working Capital | 438.35M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | 33.15M |
| Capital Expenditures | -3.30M |
| Depreciation & Amortization | 7.46M |
| Net Borrowing | -272,000 |
| Free Cash Flow | 29.85M |
| FCF Per Share | $0.10 |
Margins
| Measure | Value |
|---|
| Gross Margin | 88.50% |
| Operating Margin | 5.44% |
| Pretax Margin | 0.03% |
| Profit Margin | -4.27% |
| EBITDA Margin | 6.61% |
| EBIT Margin | 5.44% |
| FCF Margin | 4.71% |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -1.31% |
| Shareholder Yield | -1.31% |
| Earnings Yield | -0.60% |
| FCF Yield | 0.66% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $27.25 |
| Price Target Difference | 88.06% |
| Analyst Consensus | Buy |
| Analyst Count | 9 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | -0.52 |
| Piotroski F-Score | 4 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |